JBC PeproTech; Our Business is Cytokines!

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M704064200 on February 18, 2008

J. Biol. Chem., Vol. 283, Issue 17, 11700-11713, April 25, 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
283/17/11700    most recent
M704064200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by To, C.
Right arrow Articles by Di Guglielmo, G. M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by To, C.
Right arrow Articles by Di Guglielmo, G. M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

The Synthetic Triterpenoid 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic Acid-Imidazolide Alters Transforming Growth Factor β-dependent Signaling and Cell Migration by Affecting the Cytoskeleton and the Polarity Complex*Formula

Ciric To{ddagger}, Sarang Kulkarni§, Tony Pawson§, Tadashi Honda, Gordon W. Gribble, Michael B. Sporn||1, Jeffrey L. Wrana§2, and Gianni M. Di Guglielmo{ddagger}3

From the {ddagger}Department of Physiology and Pharmacology, University of Western Ontario, London, Ontario N6A 5C1, Canada, the §Programme in Molecular Biology and Cancer, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario M5G 1X5, Canada, the Department of Chemistry, Dartmouth College, Hanover, New Hampshire 03755, and the ||Department of Pharmacology, Dartmouth Medical School, Hanover, New Hampshire 03755

The anti-tumor synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO)-imidazolide (CDDO-Im) ectopically activates the transforming growth factor β (TGFβ)-Smad pathway and extends the duration of signaling by an undefined mechanism. Here we show that CDDO-Imdependent persistence of Smad2 phosphorylation is independent of Smad2 phosphatase activity and correlates with delayed TGFβ receptor degradation and trafficking. Altered TGFβ trafficking parallels the dispersal of EEA1-positive endosomes from the perinuclear region of CDDO-Im-treated cells. The effect of CDDO-Im on the EEA1 compartment led to an analysis of the cytoskeleton, and we observed that CDDO-Im alters microtubule dynamics by disrupting the microtubule-capping protein, Clip-170. Interestingly, biotinylated triterpenoid was found to localize to the polarity complex at the leading edge of migrating cells. Furthermore, CDDO-Im disrupted the localization of IQGAP1, PKC{zeta}, Par6, and TGFβ receptors from the leading edge of migrating cells and inhibited TGFβ-dependent cell migration. Thus, the synthetic triterpenoid CDDO-Im interferes with TGFβ receptor trafficking and turnover and disrupts cell migration by severing the link between members of the polarity complex and the microtubule network.


Received for publication, May 16, 2007 , and in revised form, February 8, 2008.

* This work was supported by National Cancer Institute of Canada (NCIC) Terry Fox Foundation Grant 017189 (to G. M. D. G.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Formula The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. 1-3 and Movies 1-4.

1 Supported by National Institutes of Health Grant R01 CA78814, the National Foundation for Cancer Research, and Reata Pharmaceuticals, Inc.

2 Work in the laboratory of this author was supported by grants from the NCIC and Canadian Institutes of Health Research Grant MOP-74692.

3 To whom correspondence should be addressed: Dept. of Physiology and Pharmacology, Medical Sciences Bldg., University of Western Ontario, London, Ontario N6A 5C1, Canada. Tel.: 519-661-2111 (ext. 80042); E-mail: john.diguglielmo{at}schulich.uwo.ca.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2008 by the American Society for Biochemistry and Molecular Biology.